FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to infectiology and clinical pharmacology, and aims at treating staphylococcal infections. Lyophilized composition for treating staphylococcus infections contains an antibacterial protein consisting of the amino acid sequence SEQ ID NO: 2, as well as poloxamer 188, D-sorbitol and L-histidine. Components are used in declared concentrations related to the solution prior to lyophilisation. Also provided is a method of producing said lyophilized composition for treating staphylococcus infections.
EFFECT: using the group of inventions enables higher clinical effectiveness in staphylococcus infections.
5 cl, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | 2019 |
|
RU2826120C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| PHARMACEUTICAL COMPOSITION OF ANTI-TRBV9 ANTIBODY AND USE THEREOF | 2022 |
|
RU2826886C1 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
